Posted on

Services for Covid-19 Research

About COVID-19

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. Up to now, COVID-19 has been recognized in the world, with millions of  laboratory-confirmed cases and more than several 100 thousand deaths. This novel virus spread mainly through respiratory droplets and close contact. As disease progressed, a series of complications tend to develop, especially in critically ill patients. Pathological findings showed representative features of acute respiratory distress syndrome and involvement of multiple organs. Apart from supportive care, no specific treatment has been established for COVID-19. As a novel disease, many mysteries of COVID-19 are still uncovered. VitroVivo will contribute our expertise in molecular pathology and offers SARS-CoV-2 ISH and related gene IHC services to accelerate COVID-19 investigation.

Histopathology and Molecular Pathology Services for COVID-19 Research 

1. In Situ Detection of Viral RNA Markers

Services Provided by VitroVivo  Application
 SARS-CoV-2 In Situ Hybridization (ISH) Detect specific RNA for SARS-CoV-2, S gene encoding the spike protein in situ.
 nCoV-2019-S Sense In Situ hybridization (ISH) Detect specific RNA for SARS-CoV-2, the “sense” probe targets the antisense strand of the S gen in situ.

2.  In Situ Detection of SARS-CoV-2 receptor: ACE2

Services Provided by VitroVivo   Application
Angiotensin Converting Enzyme-2 (ACE2) IHC or ISH Detect localization and expression level of SARS-CoV-2 receptor ACE2 in tissue in situ.

Reference: Shang, J. . et al. Structural basis of receptor recognition by SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2179-y (2020).

3. In Situ Detection of Cytokine Storm Markers

Services Provided by VitroVivo  Application
ISH or IHC for IL-1B, IL-6, IL2,IL10, TNFα,IFNγ, IL8,IL-12, IL-4 Detect the expression of cytokine storm markers in situ.

4. In Situ Detection of Lung Tissue/ARDS Markers

Services Provided by VitroVivo  Application
IHC or ISH for AQP5, SFTPB, RAGE (AGER), SP-D (SFTPD), KL-6 (MUC1), CC16 (SCGB1A1) Detect the expression of cytokine storm markers in situ.

5. Immunohistochemical Identification of Immune and Inflammatory cells

Services Provided by VitroVivo  Application (human)
CD3 IHC T Cell marker
CD4 IHC Helper T Cell (Th) marker
CD8 IHC Cytotoxic T Cell marker
FOXP3 IHC Regulatory T cell (Treg) marker
CD68 IHC Macrophage marker
CD80, CD86, or iNOS IHC pro-inflammatory (M1-like) Macrophage marker
CD163 or CD206 IHC anti-inflammatory (M2-like) Macrophage marker
CD56/ CD3 IHC (IF) NKT Cell (CD56+/ CD3+) and NK Cell  (CD56+and CD3-) marker
CD19 IHC B Cell marker
CD138 IHC Plasma Cell marker
CD11b IHC Myeloid Cell marker
CD45 IHC Leukocyte marker

 

Fig.   Molecular immune pathogenesis and diagnosis of COVID-19

From: X. Li et al., Molecular immune pathogenesis and diagnosis of COVID-19, Journal of Pharmaceutical Analysis, https://doi.org/10.1016/j.jpha.2020.03.001